Merck, Eisai notch full approval for Keytruda-TKI inhibitor combo in advanced endometrial...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jul 22, 2021 at 10:22 PM.

  1. #1 cafead, Jul 22, 2021 at 10:22 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,039
    Likes Received:
    3
    via The FDA on Thursday gave its full approval to a combination of Keytruda and TKI inhibitor Lenvima to treat second-line or later patients with advanced endometrial carcinoma without a genetic mismatch repair deficiency or high microsatellite instability, the drugmakers said Thursday.

    article source
     
    Quote

Reply to Thread